Securities Code: 300254 Securities Abbreviation: Qianyuan Pharmaceutical Announcement No.: 2026-065 Shanxi Qianyuan Pharmaceutical Group Co., Ltd. Announcement on Subsidiary Obtaining Drug Registration Certificate The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions. Recently, Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. (hereinafter referred to as "the Subsidiary"), a subsidiary of Shanxi Qianyuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Registration Certificate" for Perindopril Erbumine and Amlodipine Besylate Tablets (II) issued by the National Medical Products Administration. The relevant situation is hereby announced as follows: I. Basic Information of the "Drug Registration Certificate" Generic Name of Drug: Perindopril Erbumine and Amlodipine Besylate Tablets (II) Certificate Number: 2026S02116 Dosage Form: Tablets Specification: Each tablet contains 5mg of Perindopril Erbumine and 10mg of Amlodipine Besylate (
Announcement on Subsidiary Obtaining Drug Registration Certificate
✨ AI Summary
Shanxi Qianyuan Pharmaceutical Group Co., Ltd. announces that its subsidiary, Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., has obtained a Drug Registration Certificate for Perindopril Erbumine and Amlodipine Besylate Tablets (II) from the National Medical Products Administration. This product is a generic of a French originator drug and is classified as a Category 4 chemical drug. The approval is expected to enhance the company's product structure and market competitiveness, positively impacting future performance, though sales remain subject to market uncertainties.
Summary generated by AI · Always verify with source document
Full Translation
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.